Nosca-Méréprine (Noscapine Hydrochloride Monohydrate)

Noscapine acts centrally by modulating neuronal pathways in the medullary cough center, likely involving sigma‑1 receptor activity. This modulation reduces the transmission of cough signals, leading to a decrease in cough frequency and intensity without significant bronchodilation.

The appropriate dose of Nosca-Méréprine is determined by the prescribing healthcare professional based on the patient’s age, weight, clinical condition, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for noscapine hydrochloride monohydrate in pregnancy and lactation are limited. It should only be used when the potential benefit outweighs any possible risk to the fetus or infant, and alternative therapies should be considered when possible.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Noscapine is a non‑opioid antitussive that suppresses cough without the analgesic or respiratory‑depressant effects associated with codeine. While codeine carries a risk of dependence and significant sedation, noscapine generally has a more favorable safety profile, though both require medical supervision.

Store Nosca-Méréprine at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme temperature fluctuations to maintain potency and stability.

Nosca-Méréprine is administered orally. The tablet or liquid is taken with water as directed by the prescriber, usually at regular intervals to maintain consistent plasma levels and achieve optimal cough suppression.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, serious skin disorders like Stevens‑Johnson syndrome, hepatic dysfunction, hematologic abnormalities, and, in uncommon cases, seizures. Patients should seek immediate medical attention if any of these occur.

Nosca-Méréprine should be avoided in individuals with known hypersensitivity to noscapine or any excipients, in patients with severe hepatic impairment without specialist advice, and in pregnant or breastfeeding women unless the prescriber determines that the benefit outweighs the risk.